RI
PTGX icon

RTW Investments’s Protagonist Therapeutics PTGX Stock Holding History

RTW Investments’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$620M Buy
5,061,175
+2,122
+0% +$222K 5.3% 4
2026
Q1 		$533M Hold
5,059,053
– – 5.31% 3
2025
Q4 		$442M Sell
5,059,053
-697,224
-12% -$57.1M 4.43% 5
2025
Q3 		$382M Hold
5,756,277
– – 4.71% 6
2025
Q2 		$318M Buy
5,756,277
+36,862
+0.6% +$1.77M 4.53% 5
2025
Q1 		$277M Buy
5,719,415
+220,870
+4% +$9.26M 4.23% 7
2024
Q4 		$212M Buy
5,498,545
+72,433
+1% +$3.16M 3.21% 10
2024
Q3 		$244M Buy
5,426,112
+139,708
+3% +$5.64M 3.53% 9
2024
Q2 		$183M Sell
5,286,404
-29,110
-0.5% -$853K 2.84% 14
2024
Q1 		$154M Hold
5,315,514
– – 2.27% 16
2023
Q4 		$122M Sell
5,315,514
-100,000
-2% -$1.75M 1.9% 18
2023
Q3 		$90.3M Hold
5,415,514
– – 1.91% 19
2023
Q2 		$150M Buy
5,415,514
+814,715
+18% +$20.4M 2.85% 15
2023
Q1 		$106M Buy
4,600,799
+1,008,813
+28% +$16.9M 2.2% 17
2022
Q4 		$39.2M Sell
3,591,986
-584,851
-14% -$4.93M 0.8% 27
2022
Q3 		$35.2M Sell
4,176,837
-617,662
-13% -$5.84M 0.81% 34
2022
Q2 		$37.9M Hold
4,794,499
– – 0.98% 31
2022
Q1 		$114M Buy
4,794,499
+2,194,677
+84% +$61.8M 2.35% 13
2021
Q4 		$88.9M Buy
2,599,822
+846,127
+48% +$26.7M 1.3% 26
2021
Q3 		$31.1M Sell
1,753,695
-1,753,695
-50% -$74.8M 0.47% 50
2021
Q2 		$157M Hold
3,507,390
– – 2.38% 12
2021
Q1 		$90.8M Sell
3,507,390
-142,679
-4% -$3.61M 1.42% 25
2020
Q4 		$73.6M Buy
3,650,069
+241,108
+7% +$5.19M 1.23% 27
2020
Q3 		$66.6M Buy
3,408,961
+25,753
+0.8% +$483K 1.6% 20
2020
Q2 		$59.7M Buy
3,383,208
+722,816
+27% +$9.07M 1.68% 21
2020
Q1 		$18.8M Buy
2,660,392
+200,404
+8% +$1.5M 0.81% 36
2019
Q4 		$17.3M Buy
2,459,988
+1,697,705
+223% +$16.9M 0.65% 34
2019
Q3 		$9.15M Buy
+762,283
New +$9.61M 0.54% 38

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

RTW Investments's PTGX Position: Q2 2026 in Review

RTW Investments increased its Protagonist Therapeutics (PTGX) stake by 0.04% in Q2 2026, buying an estimated $222K and bringing the position to 5,061,175 shares worth $620M. The position accounts for 5.3% of the portfolio, ranked #4.

RTW Investments first reported a position in PTGX in Q3 2019 and has held it in 28 quarters since. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • RTW Investments held 5,061,175 shares of Protagonist Therapeutics worth $620M as of Q2 2026.
  • RTW Investments bought 2,122 Protagonist Therapeutics shares in Q2 2026, an estimated $222K.
  • Protagonist Therapeutics made up 5.3% of RTW Investments's portfolio in Q2 2026, its #4 holding.
  • RTW Investments first reported a position in Protagonist Therapeutics in Q3 2019 and has held it in 28 quarters since.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on RTW Investments's 13F filing for Q2 2026, filed 14 Aug 2026.